Abstracts tagged "Bone density"

Abstract Number: 0130 • ACR Convergence 2020
The Prevalence of Osteoporosis in Individuals with Osteoarthritis: A Systematic Review
Timothy Varghese¹, Ali Ahmadi Pirshahid², Dongkeun Kim² and Yueyang Li², ¹Schulich School of Medicine & Dentistry, Richmond Hill, ON, Canada, ²Schulich School of Medicine & Dentistry, London, ON, Canada
Background/Purpose: There is controversy regarding the relationship between osteoarthritis (OA) and osteoporosis (OP). While OA may be associated with increased bone mineral density (BMD) due…
Abstract Number: 1152 • 2019 ACR/ARP Annual Meeting
Low Rates of Bone Mineral Density Testing by Rheumatologists in Patients with Systemic Lupus Erythematosus and Glucocorticoid Therapy
JB Boone¹, S. Bobo Tanner ¹ and April Barnado ¹, ¹Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at an increased risk of developing osteoporosis and clinical fractures compared to healthy controls. Bone loss in…
Abstract Number: 2212 • 2019 ACR/ARP Annual Meeting
Patients with Axial Spondyloarthritis Have Abnormal Microarchitecture Despite Normal Areal Bone Mineral Density and Trabecular Bone Score by DXA
Dalit Ashany¹, Susan Goodman ², Haley Tornberg ¹, Donald McMahon ³, Douglas Mintz ⁴, Linda Russell ⁵ and Emily Stein ¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital For Special Surgery/Weill Cornell Medicine, New York, NY, ³Donald J.McMahon Statistical Consulting, South Nyack, NY, ⁴Hospital for Special Surgery, Division of Radiology and Imaging, New York, ⁵Hospital for Special Surgery, New York
Background/Purpose: Axial Spondyloarthritis (axSpA) is characterized by abnormal bone formation that produces syndesmophytes, while paradoxically, inflammation causes increased bone resorption and skeletal fragility. Detection of…
Abstract Number: 2219 • 2019 ACR/ARP Annual Meeting
Randomized Control Study in Glucocorticoid-Induced Osteoporosis Treated with Bisphosphonate or Denosumab (GOBID)
Ikuko Tanaka¹, Mari Ushikubo ², Misako Konishi ², Yutaro Hayashi ², Satoshi Hama ³, Keisuke Izumi ², Yutaka Okano ², Shigenori Tamaki ⁴ and Hisaji Ohshima ², ¹Nagoya Rheumatology Clinic, Ngoya, Japan, ²National Tokyo Medical Center, Tokyo, Japan, ³tokyo medical center, tokyo, Japan, ⁴Nagoya Rheumatology Clinic, Nagoya, Japan
Background/Purpose: It has not been established which therapy, bisphosphonates or denosumab, is more effective for glucocorticoid-induced osteoporosis (GIO). The purpose of this study was to…
Abstract Number: 2222 • 2019 ACR/ARP Annual Meeting
Bone Health: An Independent Predictor of Coronary Artery Disease
Lilian Bizzocchi¹, Maria Salgado ¹, Bhavin Chokshi ¹, Navneet Kaur ¹, Oscar Mena ¹ and Michal Packman ², ¹Jacobi Medical Center, Bronx, NY, ²North Central Bronx Hospital, Bronx, NY
Background/Purpose: An association between low bone mineral density (BMD) and cardiovascular events has been shown. The calcification process observed in atherosclerosis and bone mineralization have…
Abstract Number: 2228 • 2019 ACR/ARP Annual Meeting
Rheumatoid Arthritis Disease Activity Is Associated with Low Femoral Neck Bone Mineral Density in a Diverse Cohort of Patients
Katherine Wysham¹, Jonathan Graf ², Jane Shofer ³, Dennis Black ², James Andrews ³, Dolores Shoback ² and Patricia Katz ², ¹Veterans Health Administration Puget Sound, Seattle WA, Seattle, ²University of California, San Francisco, San Francisco, CA, ³University of Washington, Seattle, WA
Background/Purpose: Rheumatoid arthritis (RA) is an independent risk factor for osteoporosis (OP) and fracture. Although several OP risk factors are well-described in RA, many mechanisms…
Abstract Number: 2232 • 2019 ACR/ARP Annual Meeting
Results of the Implementation of a Bone Health Program in Patients with Rheumatoid Arthritis to Improve the Evaluation of Osteoporosis
Gabriel Figueroa-Parra¹, Rita Pineda-Sic ², Jairo Rodriguez-Hinojosa ³, Carmen Magdalena Gamboa-Alonso ⁴, Ana De-Leon-Ibarra ³, Janett Carmen Riega Torres ⁵, Iván de Jesús Hernández-Galarza ², Dionicio Galarza-Delgado ² and Cassandra Skinner Taylor ², ¹Universidad Autónoma de Nuevo León, "Hospital Universitario Dr. José Eleuterio González", Monterrey, Nuevo Leon, Mexico, ²Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr Jose Eleuterio Gonzalez", Monterrey, Nuevo Leon, Mexico, ³Universidad Autónoma de Nuevo León, "Hospital Universitario Dr. José Eleuterio González", Monterrey, Mexico, ⁴Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ⁵Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr Jose Eleuterio Gonzalez", Monterrey, Mexico
Background/Purpose: Osteoporosis is a generalized skeletal disorder characterized by compromised bone strength and deterioration of quality, often leading to fragility fractures (1). People with rheumatoid…
Abstract Number: 2299 • 2018 ACR/ARHP Annual Meeting
Subgroup Analysis of the Effect of Denosumab Compared with Risedronate on Percentage Change in Lumbar Spine Bone Mineral Density at 24 Months in Glucocorticoid-Treated Individuals
Kenneth Saag¹, Nicola Pannacciulli², Piet Geusens³, Jonathan D. Adachi⁴, Eric Lespessailles⁵, Jorge Malouf⁶, Bente Langdahl⁷, Peter W. Butler², Xiang Yin² and Willem F. Lems⁸, ¹University of Alabama, Birmingham, AL, ²Amgen Inc., Thousand Oaks, CA, ³Maastricht University, Maastricht, Netherlands, ⁴McMaster University, Hamilton, ON, Canada, ⁵University Hospital Orleans, Orleans, France, ⁶Hospital San Pablo, Barcelona, Spain, ⁷Aarhus University, Aarhus, Denmark, ⁸VU University Medical Centre, Amsterdam, Netherlands
Background/Purpose: We previously demonstrated that denosumab increased lumbar spine and total hip bone mineral density (BMD) significantly more than risedronate at 12 and 24 months…
Abstract Number: 2300 • 2018 ACR/ARHP Annual Meeting
Compliance with Screening and Supplementation Guidelines for Glucocorticoid-Induced Osteoporosis, How Bad Did We Do This Time?
John Zawidniak¹ and John Waterman², ¹Rheumatology, University of Connecticut, Farmington, CT, ²Rheumatology, Connecticut VA Healthcare System, Newington, CT
Background/Purpose: Glucocorticoid-induced osteoporosis (GIOP) is a well-established and well-studied phenomenon that is a sequela of the treatment of many inflammatory diseases. Many studies over the…
Abstract Number: 2302 • 2018 ACR/ARHP Annual Meeting
Forearm Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis
Nelson B. Watts¹, Robin K. Dore², Sanford Baim³, Gary Hattersley⁴, Greg Williams⁵, Yamei Wang⁴, Tamara D. Rozental⁶ and Meryl S. LeBoff⁷, ¹Mercy Health Osteoporosis and Bone Health Services, Cincinnati, OH, ²Univ of California, Los Angeles, CA, ³Rush Medical College, Chicago, IL, ⁴Radius Health, Inc., Waltham, MA, ⁵Clinical Development, Radius Health, Inc., Waltham, MA, ⁶Beth Israel Deaconess Medical Center, Boston, MA, ⁷Brigham and Women's Hospital, Boston, MA
Background/Purpose: Wrist fractures are the most common fracture of the upper extremity and increase subsequent fracture risk in women with postmenopausal osteoporosis. Most wrist fractures…
Abstract Number: 2303 • 2018 ACR/ARHP Annual Meeting
Response Rates for Hip, Femoral Neck, and Lumbar Spine Bone Mineral Density in Patients Treated with Abaloparatide Followed By Alendronate
Chad Deal¹, Bruce Mitlak², Yamei Wang², Lorraine A Fitzpatrick² and Paul D Miller³, ¹Cleveland Clinic, Shaker Heights, OH, ²Radius Health, Inc., Waltham, MA, ³Colorado Center for Bone Research, Lakewood, CO
Background/Purpose: Abaloparatide (ABL) is a selective activator of the PTH1 receptor signaling pathway that stimulates bone formation. In the ACTIVE Phase 3 study, ABL significantly…
Abstract Number: 2309 • 2018 ACR/ARHP Annual Meeting
Implementation of a Primary Prevention, Population-Based Virtual Osteoporosis Clinic Dramatically Increases the Number of Rural Veterans Receiving Osteoporosis Screening and Treatment
Karla L. Miller¹, Shardool Patel², Grant W. Cannon³ and Zachary L. Anderson², ¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Salt Lake City VA Medical Center, Salt Lake City, UT, ³Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT
Background/Purpose: The delivery of osteoporosis services is sub-optimal nationally and throughout the Veterans Affairs (VA) healthcare system and particularly poor for rural Veterans. To meet…
Abstract Number: 2312 • 2018 ACR/ARHP Annual Meeting
Spontaneous Vertebral Fractures after Denosumab Discontinuation
Helena Florez¹, Julio Ramírez², Ana Monegal¹, Núria Guañabens¹ and Pilar Peris¹, ¹Department of Rheumatology, Hospital Clinic, University of Barcelona, Barcelona, Spain, ²Rheumatology, Hospital Clínic de Barcelona, Barcelona, Spain
Spontaneous Vertebral Fractures after Denosumab Discontinuation.H. Florez, J. Ramírez, A. Monegal, N. Guañabens, P. Peris. Department of Rheumatology. Hospital Clinic, University of Barcelona. Background/Purpose: Denosumab…
Abstract Number: 2315 • 2018 ACR/ARHP Annual Meeting
Opportunistic Screening for Osteoporosis Using Thoraco-Abdomino-Pelvic Computed Tomography Assessing the Vertebral Density in Rheumatoid Arthritis Patients
Julia Perrier-Cornet¹, Abdou Yacoubou OMOUROU², Marine FAUNY¹, Damien Loeuille³ and Isabelle Chary-Valckenaere⁴, ¹Rheumatology, University Hospital of Nancy, VANDOEUVRE LES NANCY, France, ²Inserm, CIC-1433 Clinical Epidemiology, University Hospital of Nancy, VANDOEUVRE LES NANCY, France, ³Rheumatology, University Hospital of Nancy, NANCY, France, ⁴Rheumatology, CHRU Nancy, Vandoeuvres les Nancy, France
Background/Purpose: Screening for osteoporosis is crucial in rheumatoid arthritis (RA) patients. The aim of this study was to assess the value of thoraco-abdomino-pelvic CT-derived bone…
Abstract Number: 2322 • 2018 ACR/ARHP Annual Meeting
Intervals of Bone Mineral Density Measurement during Treatment for Osteoporosis in Patients with Rheumatoid Arthritis
Seung Yun Lee¹, Seong Ryul Kwon¹, Mie Jin Lim², Kyong-Hee Jung³ and Won Park⁴, ¹Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, Korea, Republic of (South), ²Division of Rheumatology, Departments of Internal Medicine, Inha University Hospital, Incheon, Korea, Republic of (South), ³Rheumatology, Inha University Hospital, Incheon, Korea, Republic of (South), ⁴Medicine/Rheumatology, Inha University Hospital, Incheon, Korea, Republic of (South)
Background/Purpose: There is controversy about the intervals of retesting bone mineral density (BMD) in patients treated for osteoporosis. The objective of this study is to…

« Previous Page
1
…
4
5
6
7
8
…
14
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.